TY - JOUR
T1 - Single-vessel coronary artery stenosis
T2 - Myocardial perfusion imaging with gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine
AU - Gerber, Bernhard L.
AU - Bluemke, David A.
AU - Chin, Bennett B.
AU - Boston, Raymond C.
AU - Heldman, Alan W.
AU - Lima, João A.C.
AU - Kraitchman, Dara L.
PY - 2002/10/1
Y1 - 2002/10/1
N2 - PURPOSE: To evaluate the ability of Gadomer-17 to depict perfusion defects in a closed-chest swine model of single-vessel coronary artery disease. MATERIALS AND METHODS: Twelve pigs underwent closed-chest placement of a flow reducer for 70%-90% luminal stenosis in the proximal left anterior coronary artery. Magnetic resonance (MR) perfusion imaging with Gadomer-17 and gadopentetate dimeglumine, microsphere blood flow (MBF) testing, and technetium 99m (99mTc) 2 methoxyisobutylisonitrile (MIBI) single photon emission computed tomography (SPECT) were performed during dipyridamole vasodilation. Comparisons of percentage signal intensity (SI) increase (PSIC) in remote and ischemic myocardium were made with repeated measurements analysis of variance after injection of both tracers. RESULTS: Perfusion defects and reduced PSIC in the anterior ischemic versus the inferior remote myocardium could be identified after injection of both Gadomer-17 (PSIC, 66% ± 30 [mean ± SD] vs 100% ± 32, respectively; P < .001) and gadopentetate dimeglumine (PSIC, 49% ± 31 vs 81% ± 43, respectively; P < .005). The size of perfusion defect depicted with both tracers was highly correlated with defect size at 99mTc MIBI SPECT (r = 0.69, P < .05 for Gadomer-17 and r = 0.60, P = .05 for gadopentetate dimeglumine) and with areas of reduced MBF (r = 0.70, P < .05 for Gadomer-17 and r = 0.80, P < .05 for gadopentetate dimeglumine). PSIC also correlated with MBF(r= 0.89, P < .001 for Gadomer-17 and r= 0.75, P< .001 for gadopentetate dimeglumine). Gadomer-17 allowed differentiation of ischemic from nonischemic myocardium, as demonstrated by reduced PSIC (PSIC, 48% ± 38 vs 72% ± 31, respectively; P < .001) until 20 minutes after contrast material injection. In contrast, differentiation of ischemic from nonischemic myocardium was possible only until 55 seconds after injection of gadopentetate dimeglumine (PSIC, 36% ± 24 vs 56% ± 27, respectively; P < .005) but not at any time point thereafter. CONCLUSION: With the study conditions, Gadomer-17 provided more prolonged differentiation of ischemic from remote myocardium than that with gadopentetate dimeglumine.
AB - PURPOSE: To evaluate the ability of Gadomer-17 to depict perfusion defects in a closed-chest swine model of single-vessel coronary artery disease. MATERIALS AND METHODS: Twelve pigs underwent closed-chest placement of a flow reducer for 70%-90% luminal stenosis in the proximal left anterior coronary artery. Magnetic resonance (MR) perfusion imaging with Gadomer-17 and gadopentetate dimeglumine, microsphere blood flow (MBF) testing, and technetium 99m (99mTc) 2 methoxyisobutylisonitrile (MIBI) single photon emission computed tomography (SPECT) were performed during dipyridamole vasodilation. Comparisons of percentage signal intensity (SI) increase (PSIC) in remote and ischemic myocardium were made with repeated measurements analysis of variance after injection of both tracers. RESULTS: Perfusion defects and reduced PSIC in the anterior ischemic versus the inferior remote myocardium could be identified after injection of both Gadomer-17 (PSIC, 66% ± 30 [mean ± SD] vs 100% ± 32, respectively; P < .001) and gadopentetate dimeglumine (PSIC, 49% ± 31 vs 81% ± 43, respectively; P < .005). The size of perfusion defect depicted with both tracers was highly correlated with defect size at 99mTc MIBI SPECT (r = 0.69, P < .05 for Gadomer-17 and r = 0.60, P = .05 for gadopentetate dimeglumine) and with areas of reduced MBF (r = 0.70, P < .05 for Gadomer-17 and r = 0.80, P < .05 for gadopentetate dimeglumine). PSIC also correlated with MBF(r= 0.89, P < .001 for Gadomer-17 and r= 0.75, P< .001 for gadopentetate dimeglumine). Gadomer-17 allowed differentiation of ischemic from nonischemic myocardium, as demonstrated by reduced PSIC (PSIC, 48% ± 38 vs 72% ± 31, respectively; P < .001) until 20 minutes after contrast material injection. In contrast, differentiation of ischemic from nonischemic myocardium was possible only until 55 seconds after injection of gadopentetate dimeglumine (PSIC, 36% ± 24 vs 56% ± 27, respectively; P < .005) but not at any time point thereafter. CONCLUSION: With the study conditions, Gadomer-17 provided more prolonged differentiation of ischemic from remote myocardium than that with gadopentetate dimeglumine.
KW - Animals
KW - Heart perfusion
KW - MR
KW - Magnetic resonance (MR), contrast media
KW - Magnetic resonance (MR)contrast enhancement
KW - Myocardium
KW - Myocardium, blood supply
KW - SPECT
UR - http://www.scopus.com/inward/record.url?scp=0036788282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036788282&partnerID=8YFLogxK
U2 - 10.1148/radiol.2251011377
DO - 10.1148/radiol.2251011377
M3 - Article
C2 - 12354992
AN - SCOPUS:0036788282
SN - 0033-8419
VL - 225
SP - 104
EP - 112
JO - Radiology
JF - Radiology
IS - 1
ER -